LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Hormone Analogues with Unique Signaling Profiles from Replacement of α-Residue Triads with β/γ Diads.

    Gibadullin, Ruslan / Kim, Tae Wook / Tran, Lauren My-Linh / Gellman, Samuel H

    Journal of the American Chemical Society

    2023  Volume 145, Issue 37, Page(s) 20539–20550

    Abstract: We have applied an underexplored backbone modification strategy to generate new analogues of peptides that activate two clinically important class B1 G protein-coupled receptors (GPCRs). Most peptide modification strategies involve changing side chains ... ...

    Abstract We have applied an underexplored backbone modification strategy to generate new analogues of peptides that activate two clinically important class B1 G protein-coupled receptors (GPCRs). Most peptide modification strategies involve changing side chains or, less commonly, changing the configuration at side chain-bearing carbons (i.e., l residues replaced by d residues). In contrast, backbone modifications alter the number of backbone atoms and the identities of backbone atoms relative to a poly-α-amino acid backbone. Starting from the peptide agonists PTH(1-34) (the first 34 residues of the parathyroid hormone, used clinically as the drug teriparatide) and glucagon-like peptide-1 (7-36) (GLP-1(7-36)), we replaced native α-residue triads with a diad composed of a β-amino acid residue and a γ-amino acid residue. The β/γ diad retains the number of backbone atoms in the ααα triad. Because the β and γ residue each bear a single side chain, we implemented ααα→βγ replacements at sites that contained a Gly residue (i.e., at α-residue triads that presented only two side chains). All seven of the α/β/γ-peptides derived from PTH(1-34) or GLP-1(7-36) bind to the cognate receptor (the PTHR1 or the GLP-1R), but they vary considerably in their activity profiles. Outcomes include functional mimicry of the all-α agonist, receptor-selective agonist activity, biased agonism, or strong binding with weak activation, which could lead to antagonist development. Collectively, these findings demonstrate that ααα→βγ replacements, which are easily implemented via solid-phase synthesis, can generate peptide hormone analogues that display unique and potentially useful signaling behavior.
    MeSH term(s) Signal Transduction ; Parathyroid Hormone ; Amino Acids ; Carbon ; Glucagon-Like Peptide 1
    Chemical Substances Parathyroid Hormone ; Amino Acids ; Carbon (7440-44-0) ; Glucagon-Like Peptide 1 (89750-14-1)
    Language English
    Publishing date 2023-09-11
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 3155-0
    ISSN 1520-5126 ; 0002-7863
    ISSN (online) 1520-5126
    ISSN 0002-7863
    DOI 10.1021/jacs.3c06703
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Backbone Modification Provides a Long-Acting Inverse Agonist of Pathogenic, Constitutively Active PTH1R Variants.

    Liu, Shi / Daley, Eileen J / Tran, Lauren My-Linh / Yu, Zhen / Reyes, Monica / Dean, Thomas / Khatri, Ashok / Levine, Paul M / Balana, Aaron T / Pratt, Matthew R / Jüppner, Harald / Gellman, Samuel H / Gardella, Thomas J

    Journal of the American Chemical Society

    2024  Volume 146, Issue 10, Page(s) 6522–6529

    Abstract: Parathyroid hormone 1 receptor (PTH1R) plays a key role in mediating calcium homeostasis and bone development, and aberrant PTH1R activity underlies several human diseases. Peptidic PTH1R antagonists and inverse agonists have therapeutic potential in ... ...

    Abstract Parathyroid hormone 1 receptor (PTH1R) plays a key role in mediating calcium homeostasis and bone development, and aberrant PTH1R activity underlies several human diseases. Peptidic PTH1R antagonists and inverse agonists have therapeutic potential in treating these diseases, but their poor pharmacokinetics and pharmacodynamics undermine their in vivo efficacy. Herein, we report the use of a backbone-modification strategy to design a peptidic PTH1R inhibitor that displays prolonged activity as an antagonist of wild-type PTH1R and an inverse agonist of the constitutively active PTH1R-H223R mutant both in vitro and in vivo. This peptide may be of interest for the future development of therapeutic agents that ameliorate PTH1R malfunction.
    MeSH term(s) Humans ; Drug Inverse Agonism ; Receptor, Parathyroid Hormone, Type 1 ; Peptides ; Parathyroid Hormone/pharmacology
    Chemical Substances Receptor, Parathyroid Hormone, Type 1 ; Peptides ; Parathyroid Hormone ; PTH1R protein, human
    Language English
    Publishing date 2024-02-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3155-0
    ISSN 1520-5126 ; 0002-7863
    ISSN (online) 1520-5126
    ISSN 0002-7863
    DOI 10.1021/jacs.3c09694
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top